[Programme review of somatropin deficit in pediatrics at the Hospital Universitario Virgen del Rocío]

Insights

Growth hormone therapy (somatropin) effectively increased height in pediatric patients with growth hormone deficiency or born small for gestational age. Female patients aged 0-12 with growth hormone deficiency showed the best response in the first year.

Area of Science:

  • Pediatric Endocrinology
  • Growth Hormone Therapy
  • Clinical Research

Context:

  • Somatropin (growth hormone) is used to treat growth deficiencies in children.
  • Assessing treatment effectiveness is crucial for optimizing pediatric care.
  • This study reviews somatropin use at Hospital Universitario Virgen del Rocío.

Purpose:

  • To review the effectiveness of somatropin treatment in pediatric patients.
  • To compare outcomes in children with growth hormone deficiency versus those born small for gestational age.
  • To evaluate treatment efficacy during the first year of therapy.

Summary:

  • A retrospective, observational study analyzed pediatric patients receiving somatropin.
  • Patients included those with growth hormone deficiency and those born small for gestational age.
  • Growth rate increased, and bone age neared chronological age post-treatment.

Impact:

  • Somatropin treatment demonstrated high effectiveness in both patient groups.
  • A favorable increase in height was observed in treated children.
  • Female patients aged 0-12 with growth hormone deficiency exhibited the most significant response.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Hospitals-II00:59

Hospitals-II

Hospitals provide inpatient and outpatient services. Inpatient services provide care to patients that stay in the hospital for an extended period, ranging from days to months. Examples of inpatient services include intensive care units, hospital wards, or surgeries. Outpatient services provide care to patients who come to a hospital for a diagnostic or treatment but do not stay overnight —for example, diagnostic tests, surgical procedures, or health education.
Nurses that work in hospitals have...